Prelude Capital Management, LLC Biocryst Pharmaceuticals Inc Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $39,092 - $100,419	24,433 New	24,433 $49,000
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $8,967 - $13,379	-3,587 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $10,438 - $32,821	3,587 New	3,587 $14,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $8,580 - $12,652	-1,318 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $7,275 - $10,530	1,318 New	1,318 $10,000

257

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.47B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.